For instance, PTEN is rarely mutated in KRAS- and BRAF-driven human lung cancers, and yet Pten inactivation provides a very strong tumor fitness advantage in our autochthonous mouse models (Fig. 6B and Supplementary Fig. 11A, B). This evidence concerns the gene PTEN and lung cancer.